Federico Mazzotti1,2, Alessandro Cucchetti3, Yvette H M Claassen4, Amanda C R K Bos5, Esther Bastiaannet4,6, Giorgio Ercolani3, Jan Willem T Dekker7. 1. Department of Surgery, Reinier de Graaf Gasthuis, Delft, The Netherlands. mazzottifederico@gmail.com. 2. Department of Medical and Surgical Science - DIMEC, Alma Mater Studiorum - University of Bologna, Bologna, Italy. mazzottifederico@gmail.com. 3. Department of Medical and Surgical Science - DIMEC, Alma Mater Studiorum - University of Bologna, Bologna, Italy. 4. Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands. 5. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. 6. Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. 7. Department of Surgery, Reinier de Graaf Gasthuis, Delft, The Netherlands.
Abstract
BACKGROUND: An aging population combined with an increased colorectal cancer (CRC) incidence in the older population will increase its prevalence in the elderly, questioning how many years of life are lost (YLLs) in these patients. PATIENTS AND METHODS: Data from 32,568 Dutch CRC patients ≥ 80 years were used to estimate the number of YLLs after diagnosis, using a reference age-, sex- and year-of-onset-matched cohort derived from national life tables. YLLs were additionally adjusted by comorbidities. Number needed to treat (NNT) was used as measure of surgical effect size. RESULTS: Surgery was applied in 74.9% of patients leading to 1.3 YLLs, being superior in 86.1% of cases with respect to alternative therapies (YLLs 4.8 years) and resulting in a number of two patients needed to operate to achieve one positive outcome. YLLs and NNTs depended on CRC stage, patient' age and comorbidities. For Stage I-II patients in the best clinical conditions (80-85 years without comorbidities), YLLs increased up to 4.1 years after surgery and up to 8.8 years without surgery (NNT 3). For Stage III patients, the NNT of surgery varied between 2 when they were in the best clinical conditions and 4 when they were older with high comorbidities. In Stage IV patients, the NNT ranged between 6 and 31. CONCLUSIONS: YLLs represents a novel approach to evaluate CRC prognosis. Stage I-III surgical patients can have a life expectancy similar to that of general population, being the NNT of surgery reasonably small compared with alternatives. Personalized comorbidity data are needed to confirm present findings.
BACKGROUND: An aging population combined with an increased colorectal cancer (CRC) incidence in the older population will increase its prevalence in the elderly, questioning how many years of life are lost (YLLs) in these patients. PATIENTS AND METHODS: Data from 32,568 Dutch CRC patients ≥ 80 years were used to estimate the number of YLLs after diagnosis, using a reference age-, sex- and year-of-onset-matched cohort derived from national life tables. YLLs were additionally adjusted by comorbidities. Number needed to treat (NNT) was used as measure of surgical effect size. RESULTS: Surgery was applied in 74.9% of patients leading to 1.3 YLLs, being superior in 86.1% of cases with respect to alternative therapies (YLLs 4.8 years) and resulting in a number of two patients needed to operate to achieve one positive outcome. YLLs and NNTs depended on CRC stage, patient' age and comorbidities. For Stage I-II patients in the best clinical conditions (80-85 years without comorbidities), YLLs increased up to 4.1 years after surgery and up to 8.8 years without surgery (NNT 3). For Stage III patients, the NNT of surgery varied between 2 when they were in the best clinical conditions and 4 when they were older with high comorbidities. In Stage IV patients, the NNT ranged between 6 and 31. CONCLUSIONS: YLLs represents a novel approach to evaluate CRC prognosis. Stage I-III surgical patients can have a life expectancy similar to that of general population, being the NNT of surgery reasonably small compared with alternatives. Personalized comorbidity data are needed to confirm present findings.
Authors: J W T Dekker; G A Gooiker; E Bastiaannet; C B M van den Broek; L G M van der Geest; C J van de Velde; R A E M Tollenaar; G J Liefers Journal: Eur J Surg Oncol Date: 2014-06-06 Impact factor: 4.424
Authors: J J Jobsen; M J Aarts; S Siesling; J Klaase; W J Louwman; P M P Poortmans; M L M Lybeert; C C E Koning; H Struikmans; J W W Coebergh Journal: Clin Oncol (R Coll Radiol) Date: 2011-10-02 Impact factor: 4.126
Authors: K L van Rooijen; Q Shi; K K H Goey; J Meyers; V Heinemann; E Diaz-Rubio; E Aranda; A Falcone; E Green; A de Gramont; D J Sargent; C J A Punt; M Koopman Journal: Eur J Cancer Date: 2018-01-30 Impact factor: 9.162
Authors: E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold Journal: Ann Oncol Date: 2016-07-05 Impact factor: 32.976
Authors: Hyunsoon Cho; Carrie N Klabunde; K Robin Yabroff; Zhuoqiao Wang; Angela Meekins; Iris Lansdorp-Vogelaar; Angela B Mariotto Journal: Ann Intern Med Date: 2013-11-19 Impact factor: 25.391